Drug news
Unituxin (dinutuximab) not cost-effective to treat neuroblastoma in children according to NICE- United Therapeutics
The National Institute for Health and Care Excellence (NICE) in draft guidelines has recommended that Unituxin (dinutuximab) from United Therapeutics for high risk neuroblastoma in patients aged 12 months to 17 years is not a cost-effective use of NHS resources, at £139,600 per quality-adjusted life year (QALY) gained.